Stéphane Paul

Overview

Best Publications

• Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases

  Xavier Roblin;Hubert Marotte;Melanie Rinaudo;Emilie Del Tedesco

  330
  Citations

• A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity.

  Vincent Legros;Vincent Legros;Solène Denolly;Manon Vogrig;Bertrand Boson

  319
  Citations

• Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.

  Stephane Paul;Emilie Del Tedesco;Hubert Marotte;Melanie Rinaudo-Gaujous

  268
  Citations

• Gene-based vaccines and immunotherapeutics

  Margaret Liu;Bruce Acres;Jean-Marc Balloul;Nadine Bizouarne

  259
  Citations

• New insights in mucosal vaccine development

  Vincent Pavot;Nicolas Rochereau;Christian Genin;Bernard Verrier

  239
  Citations

• Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases

  Xavier Roblin;M Rinaudo;E Del Tedesco;J M Phelip

  220
  Citations

• Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination.

  Bruno Pozzetto;Vincent Legros;Vincent Legros;Sophia Djebali;Véronique Barateau

  211
  Citations

• Dectin-1 Is Essential for Reverse Transcytosis of Glycosylated SIgA-Antigen Complexes by Intestinal M Cells

  Nicolas Rochereau;Daniel Drocourt;Eric Perouzel;Vincent Pavot

  187
  Citations

• Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis

  Anthony Lopez;Xavier Mariette;Hervé Bachelez;Alexandre Belot

  161
  Citations

• Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting

  Alice Gutjahr;Capucine Phelip;Anne-Line Coolen;Claire Monge

  155
  Citations

• Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

  Nicolas Williet;Gilles Boschetti;Marion Fovet;Thomas Di Bernado

  145
  Citations

• Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab

  B. Ungar;U. Kopylov;T. Engel;M. Yavzori

  142
  Citations

• Receptor and nonreceptor protein tyrosine phosphatases in the nervous system.

  S. Paul;P. J. Lombroso

  141
  Citations

• Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial

  Xavier Roblin;Nicolas Williet;Gilles Boschetti;Jean-Marc Phelip

  141
  Citations

• Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open‐label, prospective and randomised clinical trial

  X. Roblin;G. Boschetti;N. Williet;Stéphane Nancey

  138
  Citations

• Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study

  W. Yacoub;N. Williet;L. Pouillon;T. Di-Bernado

  136
  Citations

• Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery.

  Vincent Pavot;Morgane Berthet;Julien Rességuier;Sophie Legaz

  129
  Citations

• Combination of C-reactive protein, infliximab trough levels and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease

  X. Roblin;H. Marotte;M. Leclerc;E. Del Tedesco

  129
  Citations

• Traffic of poly(lactic acid) nanoparticulate vaccine vehicle from intestinal mucus to sub-epithelial immune competent cells.

  Charlotte Primard;Nicolas Rochereau;Elsa Luciani;Christian Genin

  127
  Citations

• Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis.

  Amelie Carla Moreau;Stephane Paul;Emilie Del Tedesco;Melanie Rinaudo-Gaujous

  120
  Citations

• Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs.

  Jonathan Lopez;Marine Mommert;William Mouton;William Mouton;Andrés Pizzorno

  119
  Citations